HomeHealthcare & Life Sciences Alzheimers Drug Market

Global Alzheimers Drug Market Size, Share & Trends Analysis Report By Drug Class (Cholinesterase InhibitorsÂ DonepezilÂ RivastigmineÂ GalantamineÂ , NMDA Receptor AntagonistsÂ MemantineÂ , Combination DrugsÂ Donepezil + MemantineÂ , Anti-Amyloid Monoclonal AntibodiesLecanemab (Leqembi)Â Aducanumab (Aduhelm)Â Donanemab (under review)Â ), By Disease StageÂ (Early Stage / Mild AlzheimerâsÂ , Moderate AlzheimerâsÂ , Severe AlzheimerâsÂ , Prodromal / Mild Cognitive Impairment (MCI)Â ), By Coun

Starting From
USD 3950

Buy Now

Report Benefits

Develop business strategies by understanding the trends shaping and driving the Market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track sales in the global and country-specific Market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Alzheimers Drug Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Alzheimers Drug Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Alzheimers Drug Market, By Drug Class
1. Introduction
  1. Market Size and Forecast, By Drug Class
2. Cholinesterase Inhibitors
  1. Market Size and Forecast, By Region
  2. Donepezil
    1. Market Size and Forecast, By Region
  3. Rivastigmine
    1. Market Size and Forecast, By Region
  4. Galantamine
    1. Market Size and Forecast, By Region
3. NMDA Receptor Antagonists
  1. Market Size and Forecast, By Region
  2. Memantine
    1. Market Size and Forecast, By Region
4. Combination Drugs
  1. Market Size and Forecast, By Region
  2. Donepezil + Memantine
    1. Market Size and Forecast, By Region
5. Anti-Amyloid Monoclonal Antibodies
  1. Market Size and Forecast, By Region
  2. Lecanemab (Leqembi)
    1. Market Size and Forecast, By Region
  3. Aducanumab (Aduhelm)
    1. Market Size and Forecast, By Region
  4. Donanemab (under review)
    1. Market Size and Forecast, By Region
6. Tau Aggregation Inhibitors
  1. Market Size and Forecast, By Region
  2. Others
    1. Market Size and Forecast, By Region
  3. Anti-inflammatory drugs
    1. Market Size and Forecast, By Region
  4. Insulin resistance modulators
    1. Market Size and Forecast, By Region
  5. Neuroprotective agents
    1. Market Size and Forecast, By Region
Alzheimers Drug Market, By Disease Stage
1. Introduction
  1. Market Size and Forecast, By Disease Stage
2. Early Stage / Mild Alzheimer’s
  1. Market Size and Forecast, By Region
3. Moderate Alzheimer’s
  1. Market Size and Forecast, By Region
4. Severe Alzheimer’s
  1. Market Size and Forecast, By Region
5. Prodromal / Mild Cognitive Impairment (MCI)
  1. Market Size and Forecast, By Region
Alzheimers Drug Market, By Mechanism of Action
1. Introduction
  1. Market Size and Forecast, By Mechanism of Action
2. Amyloid Beta Inhibitors
  1. Market Size and Forecast, By Region
  2. Tau Protein Modulators
    1. Market Size and Forecast, By Region
  3. Neurotransmitter Modifiers
    1. Market Size and Forecast, By Region
  4. Anti-inflammatory Agents
    1. Market Size and Forecast, By Region
3. Others
  1. Market Size and Forecast, By Region
  2. Mitochondrial stabilizers
    1. Market Size and Forecast, By Region
  3. Synaptic function enhancers
    1. Market Size and Forecast, By Region
Alzheimers Drug Market, By Drug Type
1. Introduction
  1. Market Size and Forecast, By Drug Type
2. Biologics
  1. Market Size and Forecast, By Region
3. Small Molecules
  1. Market Size and Forecast, By Region
Alzheimers Drug Market, By Distribution Channel
1. Introduction
  1. Market Size and Forecast, By Distribution Channel
2. Hospital Pharmacies
  1. Market Size and Forecast, By Region
3. Retail Pharmacies
  1. Market Size and Forecast, By Region
4. Online Pharmacies
  1. Market Size and Forecast, By Region
Alzheimers Drug Market, By End User
1. Introduction
  1. Market Size and Forecast, By End User
2. Hospitals
  1. Market Size and Forecast, By Region
3. Specialty Clinics and Neurology Centers
  1. Market Size and Forecast, By Region
4. Homecare Settings
  1. Market Size and Forecast, By Region
5. Academic and Research Institutions
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  2. U.S.
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  2. U.K.
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  2. China
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  3. South Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  2. UAE
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  2. Brazil
    1. By Drug Class
      1. Cholinesterase Inhibitors
      2. NMDA Receptor Antagonists
      3. Combination Drugs
      4. Anti-Amyloid Monoclonal Antibodies
      5. Tau Aggregation Inhibitors
    2. By Disease Stage
      1. Early Stage / Mild Alzheimer’s
      2. Moderate Alzheimer’s
      3. Severe Alzheimer’s
      4. Prodromal / Mild Cognitive Impairment (MCI)
    3. By Mechanism of Action
      1. Amyloid Beta Inhibitors
      2. Others
    4. By Drug Type
      1. Biologics
      2. Small Molecules
    5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. By End User
      1. Hospitals
      2. Specialty Clinics and Neurology Centers
      3. Homecare Settings
      4. Academic and Research Institutions
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2025
1. Introduction
2. Alzheimers Drug Market Share Analysis, 2025 (%)
  1. Market Share Analysis, 2025
  2. Competition Ranking, 2025
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Eisai Co., Ltd.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Biogen Inc.
3. Eli Lilly and Company
4. Roche Holding AG
5. AbbVie Inc.
6. Johnson & Johnson
7. Novartis AG
8. Pfizer Inc.
9. Otsuka Pharmaceutical Co., Ltd.
10. Lundbeck A/S
11. Sanofi
12. BioArctic AB
13. Denali Therapeutics Inc.

Report Benefits

Table of Contents